EyePoint, Inc. (EYPT) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Eyepoint, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.739 Good morning. My name is Antoine and I'll be your conference operator today. 00:00:04.739 -- 00:00:10.208 At this time, I would like to welcome everyone to the iPoint second quarter 2025 financial 00:00:10.208 -- 00:00:13.895 results and recent corporate developments conference call. 00:00:13.895 -- 00:00:17.681 There will be a question and answer session to follow the completion of the prepared 00:00:17.681 -- 00:00:24.069 remarks. Please be advised that this call is being recorded at the company's request. 00:00:24.069 -- 00:00:28.356 I would now like to turn the call over to George Elston, Executive Vice President and 00:00:28.356 -- 00:00:32.138 Chief Financial Officer of iPoint. 00:00:32.642 -- 00:00:36.828 Thank you, and thank you all for joining us on today's conference call to discuss iPoint's 00:00:36.828 -- 00:00:41.895 second quarter 2025 financial results and recent corporate developments. 00:00:41.895 -- 00:00:46.572 With me today is Dr. Jay Duker, President and Chief Executive Officer of iPoint. 00:00:46.572 -- 00:00:50.898 Jay will begin with a review of recent corporate updates and discuss the ongoing clinical 00:00:50.898 -- 00:00:53.522 trials for Duravue and WED-AMD. 00:00:53.522 -- 00:00:58.068 I will close with commentary on the second quarter of 2025 financial results, and we 00:00:58.068 -- 00:01:01.052 will then open the call for your questions. 00:01:01.052 -- 00:01:05.078 Earlier this morning, we issued a press release detailing our financial results and recent 00:01:05.078 -- 00:01:09.384 corporate developments. A copy of the release can be found on the Investor Relations 00:01:09.384 -- 00:01:14.048 tab on the company website, www.ipointpharma.com. 00:01:15.833 -- 00:01:20.259 Before we begin our formal ...